SPP1 Specific Neutra™ Antibody Products

SPP1 (Secreted Phosphoprotein 1) plays a role in osteoclast adherence to the mineralized bone matrix, being secreted and exhibiting high-affinity binding to hydroxyapatite. The osteoclast vitronectin receptor, present on the cell membrane, potentially participates in the interaction with SPP1. Additionally, SPP1 functions as a cytokine, enhancing the expression of interferon-gamma and interleukin-12, and is integral to the pathway leading to type I immunity. Relevant pathways involving SPP1 encompass the integrin pathway and ERK signaling.

Its Gene ID: 6696, UniProtKB ID: P10451, and OMIM ID: 166490.

SPP1 Related Pathway

SPP1 holds significance in tumor therapy. Enhanced SPP1 expression correlates with M2-like TAM accumulation in esophageal squamous cell carcinoma (ESCC). Knockdown of SPP1 notably impedes M2 TAM infiltration in xenograft tumors. Functionally, SPP1 engages macrophages and promotes M2 polarization via CD44/PI3K/AKT signaling activation, thereby stimulating the secretion of VEGFA and IL6 to maintain ESCC advancement. Consequently, SPP1 presents itself as a viable therapeutic avenue in the management of ESCC.

Additionally, SPP1 exerts pro-fibrotic effects in atrial fibrosis. It triggers the TGF-β/SREBP2 signaling pathway, upregulating PCSK9 expression, and inducing mtDNA damage through this mechanism.

Fig. 1 Elucidating the molecular mechanism of SPP1 in atrial fibrosis.^{1, 4}

Utilizations of Anti-SPP1 Antibodies

• Unveiling the Promise of Anti-SPP1 Antibodies in ESCC Diagnosis

ESCC presents a bleak prognosis primarily due to the absence of effective diagnostic indicators. Anomalies in SPP1 protein expression have been documented across various cancers. Immunohistochemical assessment reveals a notable upregulation of SPP1 protein in ESCC tissues in contrast to adjacent normal tissues. ELISA analyses exhibit a significant escalation in serum autoantibody levels targeting SPP1 in ESCC compared to controls, in both discovery and validation cohorts. These findings underscore the potential utility of anti-SPP1 autoantibodies as novel biomarkers for ESCC detection.

Fig. 2 Immunohistochemical profiling reveals high SPP1 expression in human ESCC tissues.^{2, 4}

• Therapeutic Prospects of Anti-SPP1 Antibody for AMD Management

Age-related macular degeneration (AMD) stands as the leading factor behind vision loss in aged populations across Western communities. SPP1 emerges as a highly expressed gene in retinal microglia during choroidal neovascularization (CNV) progression. Intravitreal administration of an anti-SPP1 antibody notably augments lesion size relative to IgG-treated control eyes, indicating the anti-angiogenic properties of SPP1. These findings underscore the significance of SPP1 in CNV development and present potential therapeutic avenues by targeting the SPP1 pathway.

Fig. 3 Impact of SPP1 protein modulation on experimental choroidal neovascularization outcome.^{3, 4}

Creative Biolabs offers a diverse range of SPP1-targeting antibodies tailored for research endeavors and exploration of therapeutic strategies against various ailments, including cancers. Moreover, our panel of specialists stands ready to provide customized blocking or neutralizing antibody options centered around SPP1 upon inquiry.

REFERENCES

1. Stuible, Matthew, et al. "Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption." Journal of Biological Chemistry 289.10 (2014): 6498-6512.
2. Wang, Chen, et al. "Serum anti-SPP1 autoantibody as a potential novel biomarker in detection of esophageal squamous cell carcinoma." BMC cancer 22.1 (2022): 932.
3. Schlecht, Anja, et al. "Secreted phosphoprotein 1 expression in retinal mononuclear phagocytes links murine to human choroidal neovascularization." Frontiers in Cell and Developmental Biology 8 (2021): 618598.
4. Distributed under Open Access license CC BY 4.0, without modification.